The European Medicines Agency has recommended the refusal of the marketing authorisation for Raylumis, a medicine intended for the treatment of pain associated with osteoarthritis.
The Agency issued its opinion on 16 September 2021. The company that applied for authorisation, Pfizer Europe MA EEIG, may ask for re-examination of the opinion within 15 days of receiving the opinion.
Questions and answers on the refusal of the marketing authorisation for Raylumis (tanezumab) (PDF/114.96 KB)
First published: 15/02/2022
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Pfizer Europe MA EEIG
|Date of opinion||
|Date of refusal of marketing authorisation||